LivaNova PLC
185 articles about LivaNova PLC
-
LivaNova to Announce First-Quarter 2024 Results
3/21/2024
LivaNova PLC, a market-leading medical technology company, will host a conference call to discuss its first-quarter 2024 results on Wednesday, May 1, 2024 at 1 p.m. London time.
-
LivaNova Announces Pricing of Private Offering of $300 Million of 2.50% Convertible Senior Notes Due 2029
3/6/2024
LivaNova PLC announced the pricing of $300 million aggregate principal amount of 2.50% convertible senior notes due 2029 to be issued in a private offering only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.
-
LivaNova to Present at the Barclays Global Healthcare Conference
3/4/2024
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will present in a fireside chat at the Barclays Global Healthcare Conference in Miami, Florida.
-
LivaNova Reports Fourth-Quarter and Full-Year 2023 Results
2/21/2024
LivaNova PLC, a market-leading medical technology company, reported results for the quarter and full year ended December 31, 2023 and issued guidance for 2024.
-
LivaNova Announces Vladimir A. Makatsaria as CEO and Board Director
2/5/2024
LivaNova PLC today announced its Board of Directors named Vladimir A. Makatsaria as the Company’s Chief Executive Officer (CEO) and a member of the Board of Directors, effective March 1, 2024.
-
LivaNova to Wind Down Advanced Circulatory Support Business Unit
1/8/2024
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that it will commence immediately with an orderly wind down of the Advanced Circulatory Support (ACS) Business Unit to increase the Company’s strategic focus on its core Cardiopulmonary (CP) and Neuromodulation Business Units.
-
LivaNova to Announce Fourth-Quarter and Full-Year 2023 Results
1/4/2024
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its fourth-quarter and full-year 2023 results on Wednesday, February 21, 2024 at 1 p.m. London time (8 a.m. Eastern Time).
-
LivaNova to Present at the Piper Sandler Healthcare Conference
11/9/2023
LivaNova PLC, a market-leading medical technology company, announced Bill Kozy, Interim Chief Executive Officer and Board Chair of LivaNova, will present in a fireside chat at the Piper Sandler Healthcare Conference in New York.
-
LivaNova Reports Third-Quarter 2023 Results
11/1/2023
LivaNova PLC, a market-leading medical technology company, reported results for the quarter ended September 30, 2023 and raised full-year 2023 revenue and adjusted diluted earnings per share guidance.
-
LivaNova to Present at the Stifel and Wolfe Healthcare Conferences
10/25/2023
LivaNova PLC announced Bill Kozy, Interim Chief Executive Officer and Board Chair of LivaNova, will present a general business update during fireside chats at two healthcare conferences in New York in November.
-
LivaNova Board Appoints J. Christopher Barry as New Director
10/6/2023
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, announced its Board of Directors has appointed J. Christopher Barry to the Board, effective today.
-
LivaNova Announces Marco Dolci, President of Cardiopulmonary, to Retire at the End of 2023
9/21/2023
LivaNova PLC, a market-leading medical technology company, announced that Marco Dolci intends to retire as President of the Cardiopulmonary Business Unit by December 31, 2023.
-
LivaNova to Announce Third-Quarter 2023 Results
9/20/2023
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its third-quarter 2023 results on Wednesday, November 1, 2023 at 12 p.m. London time (8 a.m. Eastern Time).
-
LivaNova Unveils Essenz In-Line Blood Monitor with U.S. FDA 510(k) Clearance and CE Mark
8/30/2023
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance and CE Mark for its Essenz™ In-Line Blood Monitor (ILBM), which provides accurate and continuous measurement of essential blood parameters to perfusionists throughout cardiopulmonary bypass (CPB) procedures.
-
LivaNova to Present at the Baird Global Healthcare Conference
8/24/2023
LivaNova PLC, a market-leading medical technology company, announced Bill Kozy, Interim Chief Executive Officer and Board Chair of LivaNova, will present in a fireside chat at the Baird Global Healthcare Conference in New York.
-
LivaNova Reports Second-Quarter 2023 Results
7/26/2023
LivaNova PLC, a market-leading medical technology company, reported results for the quarter ended June 30, 2023 and raised full-year 2023 guidance.
-
LivaNova to Announce Second-Quarter 2023 Results
6/14/2023
LivaNova PLC, a market-leading medical technology and innovation company, will host a conference call to discuss its second-quarter 2023 results on Wednesday, July 26, 2023 at 1 p.m. London time.
-
LivaNova Announces 150th Bipolar Depression Patient Randomized in RECOVER Clinical Study
6/13/2023
LivaNova PLC announced the 150th bipolar depression patient has been randomized in the RECOVER clinical study, “A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy™ System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression.”
-
LivaNova Reports First-Quarter 2023 Results
5/3/2023
LivaNova PLC, a market-leading medical technology and innovation company, reported results for the quarter ended March 31, 2023 and raised full-year 2023 guidance.
-
LivaNova Board of Directors Announce Leadership Changes
4/14/2023
LivaNova PLC, a market-leading medical technology and innovation company, announced that Damien McDonald has resigned as Chief Executive Officer.